Johnson & Johnson company headlines, earnings, strategy, leadership, and market-moving business updates.
Market data may be delayed. For informational purposes only. Not investment advice.
In a market commentary carried by Yahoo Finance, Jim Cramer said he prefers drug-related stocks over parts of the tech complex and cited Johnson & Johnson as an example while discussing his current stance toward the drug sector.
THE APEX TIMES
THE APEX TIMES
The company says its presbyopia-correcting TECNIS PureSee IOL is now more widely available for U.S. cataract surgery, aiming to give surgeons and patients another lens option designed to address age-related blurry near and intermediate vision.
THE APEX TIMES
The company is stepping up funding tied to an oncology strategy aimed at difficult-to-treat cancers, while JNJ shares continue to trade near elevated levels.
THE APEX TIMES
A Los Angeles jury awarded $32 million in a mesothelioma-linked talc trial, underscoring how product-liability litigation continues to compete with Johnson & Johnson’s growth priorities.
THE APEX TIMES
The verdict stems from a lawsuit alleging pleural mesothelioma caused by years of exposure to asbestos-contaminated talc linked to the company’s baby powder products.
THE APEX TIMES
On Mad Money, the host pointed to Johnson & Johnson’s drug profitability and balance-sheet strength, arguing that diversification can help investors weather sell-offs, though he did not spell out new-drug details in the reported segment.
THE APEX TIMES
The deal adds Firefly’s degrader-antibody conjugate platform, aimed at expanding J&J’s pipeline for hard-to-treat solid tumors.
THE APEX TIMES
A fresh round of late-stage readouts and regulatory updates described by Yahoo Finance highlights how new data in multiple cancer programs could shift the market’s expectations for Johnson & Johnson, even as legal and disclosure gaps remain.
THE APEX TIMES
After a strong start to 2026, Johnson & Johnson (NYSE:JNJ) has seen its shares gain sharply year to date. But recent profit pressure, biosimilar erosion and ongoing legal and regulatory overhang leave the path to $300 dependent on a clearer re-acceleration in results.
